Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician’s Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer
- Sunday, September 19, 2021, 7:29
- PR Newswire
- Add a comment
NIJMEGEN, Netherlands, Sept. 19, 2021 /PRNewswire/ — At a late-breaking oral presentation (LBA15) at the virtual 2021 ESMO Congress today, Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, reported positive results from its pivotal Phase…
About the Author
admin has written 20972 stories on this site.